XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.3
EARNINGS PER COMMON SHARE
 9 Months Ended
Sep. 30, 2025
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE EARNINGS PER COMMON SHARE
The following table reconciles the numerators and denominators of our basic and diluted earnings per common share calculations. Net income available to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.
 
Net Income Available
to Common
Shareholders
(Numerator)
Weighted Average Shares
(Denominator)
Per-Share Amount
Three Months Ended September 30, 2025   
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share
$342 87,951 $3.89 
Effect of dilutive instruments— 659 (0.03)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share
$342 88,610 $3.86 
Three Months Ended September 30, 2024   
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share
$472 95,665 $4.93 
Effect of dilutive instruments1 987 (0.04)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share
$473 96,652 $4.89 
Nine Months Ended September 30, 2025   
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share
$1,036 91,109 $11.37 
Effect of dilutive instruments— 696 (0.09)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share
$1,036 91,805 $11.28 
Nine Months Ended September 30, 2024   
Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share
$2,882 97,505 $29.56 
Effect of dilutive instruments2 1,013 (0.29)
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share
$2,884 98,518 $29.27 
Dilutive instruments during the three and nine months ended September 30, 2025 and 2024 consisted of stock options, RSUs, convertible long‑term incentive awards, deferred compensation units and dividends on subsidiary preferred stock. During the nine-month period in 2024, our dilutive instruments also included RSUs issued under USPI’s restricted stock plan.